Perhexiline

• Calcium Channel Blockers
• Cardiovascular Agents
• Vasodilator Agents
• ATC:C08EX02

• Perhexilene
• Perhexilina [Inn-Spanish]
• Perhexilinum [Inn-Latin]
• Perhexilline

• No information avaliable

C₁₉H₃₅N

No information avaliable

Perhexiline MSDS

No information avaliable

277.488 g/mol

No information avaliable

0.0608 mg/L

Solid

6.054

Tablet for oral administration (100 mg)

For the management of severe angina pectoris.

Used in the treatment of unresponsive or refractory angina. Perhexiline increases glucose metabolism at the expense of free-fatty-acid metabolism, enhancing oxygen efficiency during myocardial ischaemia. Perhexiline also potentiates platelet responsiveness to nitric oxide both in patients with angina and patients with acute coronary syndrome. The predominant mechanism of this particular perhexiline effect is an increase in platelet cGMP responsiveness. Perhexiline also may reduce the potential for nitric oxide clearance by neutrophil-derived oxygen. Perhexiline relieves symptoms of angina, improves exercise tolerance, and increases the workload needed to induce ischaemia when used as monotherapy. The primary therapeutic roles for perhexiline are as short-term therapy (less than 3 months duration) in patients with severe ischaemia awaiting coronary revascularisation or long-term therapy in patients with ischaemic symptoms refractory to other therapeutic measures.

Well absorbed (>80%) from the gastrointestinal tract following oral administration.

Oral LD50 Rat: 2150 mg/kg; Oral LD50 Mouse: 2641 mg/kg. Short term adverse effects include nausea, transient dizziness, hypoglycaemia in diabetic patients, and torsade de pointes (rare).

No information avaliable

Humans and other mammals